Interpretation of biological causes of the predisposing markers identified through Genome Wide 8 Association Studies (GWAS) remains an open question 1 . One direct and powerful way to assess the 9 genetic causality behind GWAS is through expression quantitative trait loci (eQTLs) 2 . Here we 10 describe a novel approach to estimate the tissues giving rise to the genetic causality behind a wide 11 variety of GWAS traits, using the cis-eQTLs identified in 44 tissues of the GTEx consortium 3,4 . We 12 have adapted the Regulatory Trait Concordance (RTC) score 5 , to on the one hand measure the 13 tissue sharing probabilities of eQTLs, and also to calculate the probability that a GWAS and an 14 eQTL variant tag the same underlying functional effect. We show that our tissue sharing estimates 15 significantly correlate with commonly used estimates of tissue sharing. By normalizing the GWAS-16 eQTL probabilities with the tissue sharing estimates of the eQTLs, we can estimate the tissues 17 from which GWAS genetic causality arises. Our approach not only indicates the gene mediating 18 individual GWAS signals, but also can highlight tissues where the genetic causality for an individual 19 trait is manifested. 20
we have accumulated an impressive number of GWAS findings, the vast majority of the variants 23 identified lie in the non-coding genome 7 , rendering their biological interpretation difficult. 24 Furthermore, GWAS find genetic markers associated with organismal traits, and fail to pinpoint the 25 specific tissues causing these associations 8 . Regulatory variants, like expression quantitative trait loci 26 (eQTLs), identified in multiple tissues could aid greatly in the interpretation of GWAS results not only 27 by linking the non-coding genome to genes, but also by identifying the causal tissues behind the 28 genetic associations 2, 9, 10 . The Genotype Tissue Expression (GTEx) project was founded with the 29 intention of characterizing eQTLs across multiple tissues 4 , and currently comprises 44 tissues from 30 449 individuals (70-361 samples per tissue) for a total of 7051 transcriptomes (Supplementary 31 Figure 1 ). This makes GTEx the ideal dataset to estimate tissues from which the genetic causality of a 32 GWAS trait arises. Here we aim to address this question by first, assessing the tissue sharing of 33 eQTLs (the probability of an eQTL identified in one tissue being active in another tissue) on an 34 individual variant basis, and then using these tissue sharing estimates to infer the tissues where 35 GWAS variants exert their function. 36
For a given eQTL discovered in one tissue, we wanted to derive the probability that this eQTL is 37 active in each of the other 43 tissues. We have previously described the Regulatory Trait 38 Concordance (RTC) score, which tests whether co-localizing GWAS and eQTL variants (two variants 39 that fall into the same genomic region delimited by recombination hotspots) are tagging the same 40 functional variant 5 (Supplementary Methods & Supplementary Figure 3) . This method can easily be 41 extended to assess tissue sharing between eQTLs identified in two separate tissues (Supplementary 42 Methods). However, the RTC score is not a probability in itself and is affected by the number of 43 variants and the linkage disequilibrium (LD) in a given region. Therefore, we derived a probability 44 from the RTC score by simulating two scenarios for each region: (1) two variants tagging different 45 functional effects (H0) and (2) two variants tagging the same functional effect (H1). Subsequently we 46 generate a distribution centered on the real RTC found in the region and quantify the overlap 47 between this distribution and simulated RTC scores under H0 and H1. We then apply the Bayes' 48 theorem, in conjunction with the overall tissue sharing estimates found by the π 1 statistic 11 , to 49 compute a probability of shared functional effect, which we call P(Shared), for a given RTC score in a 50 given region (Supplementary Methods, Supplementary Figure 4 Figure 6) . By converting the RTC score into a probability we create a metric that 52 accounts for the differential power of calling shared functional effects in different regions and which 53 can be used in discovering tissue specificity of eQTLs. 54
Having a probability of sharing between two variants allows us to estimate tissue sharing of eQTLs 55 amongst the 44 GTEx tissues. The gold standard methods used to quantify tissue sharing of eQTLs, 56 such as the π 1 method, estimate overall sharing, thus we aimed to estimate individual tissue sharing 57 probabilities of each eQTL using π 1 as a baseline. In order to ascertain a near-complete list of cis-58 eQTLs, we conducted a conditional cis-eQTL discovery and identify 858-13259 independent cis-59 eQTLs at FDR = 5% (Supplementary Methods, Supplementary Figure 2 ). Subsequently we took the 60 union of eQTLs identified in all of the tissues (Supplementary Methods) and calculated sharing 61 probabilities using the methodology described in the previous paragraph. We find a high degree of 62 sharing amongst biologically related tissues. For example, brain tissues form a cluster with high 63 sharing amongst themselves, coronary artery eQTLs are shared the most with aorta, and the uterus 64 and ovaries share the most eQTLs (Figure 1a , Supplementary Table 1 ). We compared these tissue 65
sharing estimates to the more commonly used π 1 estimates 11 and find that the two metrics are 66 significantly positively correlated (r = 0.933, p < 1e-300, Figure 1b ), confirming the validity of our 67 approach. The advantage of RTC over the π 1 estimates is that RTC can assess the tissue sharing 68 probabilities of an individual variant, whereas π 1 estimates the overall sharing and cannot directly 69 make a statement about individual eQTLs. 70
Unlike the π 1 estimates, our RTC-based probability of sharing can be used to find the most likely set 71 of tissues where the eQTL effect is active. This is accomplished by enumerating the sharing 72 probabilities of an eQTL in all combinations of the 44 tissues (Supplementary Methods). Moreover, 73
we record the frequency of other tissues identified in the set of most likely tissues for an eQTL. The 74 distribution of number of tissues an eQTL is likely active in show that the majority (94%) of the eQTLs 75 are shared with at least one other tissue, in agreement with previous findings 4, 12, 13 (Figure 2a) . 76 Furthermore, the number of tissues with shared effects decreases sharply as the number of tissues 77 increases, but there is a slight enrichment for eQTLs active across most or all of the 44 tissues ( Figure  78 2a). When we compare the eQTL sharing estimates among tissues for significant eQTLs found in each 79 of the tissues, we discover two classes of tissues. Whereas the majority of the tissues exhibit higher 80 degrees of tissue sharing, some tissues like testis and whole blood show a higher degree of tissue 81 specificity (Figure 2b , c, e, Supplementary Table 2 ). Since each eQTL identified in a given tissue was 82 predicted to be active in a set of other tissues, we next identified the most frequent other tissues 83 included across all these sets. This was done to measure the global impact of the individual 84 estimates, unlike the tissue sharing comparison in the previous section where we only quantify the 85 global sharing between tissues. The results indicate for tissues with biologically meaningful 86 similarity, shared eQTL effects are also more frequently observed. For example, brain tissues are 87 most similar to other brain tissues, ovaries are most similar to uterus and vagina tissues, and heart 88 left ventricle is most similar to heart arterial appendage (Figure 2d & f, Supplementary Figure 9 , 89 Supplementary Table 3 ). In summary, our methodology uncovered two types of tissues, either with 90 high degrees of tissue specificity or with high tissue sharing, and showed individual tissue sharing 91 estimates identified biologically relevant tissues as shared, indicating the RTC method is capable of 92 assessing tissue specificity on a variant by variant basis. 93
Given that GTEx comprises a wide range of tissues and our novel methodology can assess tissue 94 sharing of each eQTL variant identified in these tissues, we are in an unprecedented position to infer 95 candidate causal regulatory effects and their genes that may mediate the GWAS variants. Since RTC 96 uses only the discovered GWAS variant, we are able to test GWAS-eQTL overlaps in all known GWAS 97 variants, and were not limited to GWAS signals with available summary statistics or raw data, which 98 unfortunately is very sparse. To this end we downloaded the NCBI GWAS catalogue 7 and filtered the 99 complete list of 15929 GWAS variants to include 5751 genome-wide significant associations (p < 5e-100 8) that overlapped with GTEx variants, and ran the RTC analysis with the independent significant 101 eQTLs (FDR = 5%) from each of the tissues, resulting in 4664 GWAS variants that co-localized with 102 eQTLs. We observe a large enrichment of high RTC scores across the GWAS-eQTL co-localizations 103 confirming, as previously described 5, 9, 14 , that GWAS variants frequently manifest their effects 104 through regulatory effects (Figure 3a) . We also observe a bimodal distribution for probabilities of 105 GWAS and eQTL tagging the same functional effect, where the majority of the probabilities are close 106 to 0, but there also is an enrichment for high probabilities (Figure 3b) . We have previously shown 107 that RTC score is a better estimate of the causality between two variants than other pairwise LD 108 metrics, r 2 and D' 5 . When we compare the RTC score between two variants to their r 2 , we observe 109 that high r 2 generally means a high RTC score, however there many causal links found by RTC and 110 missed when using r 2 as a metric, extending our previous finding that RTC is preferable to r 2 when 111 predicting causality (Figure 3c, Supplementary Figure 10 , Supplementary Table 4 ). Finally, we 112 tested how the probability of sharing, as calculated with our new methodology varies with the raw 113 RTC score and show that this probability behaves as expected with high RTC scores indicating a high 114 probability of shared functional effects between the GWAS and eQTL variants. However, the 115 probability is highly variable across regions that share the same RTC score, indicating the necessity of 116 calculating this probability on a region by region basis (Figure 3d) . 117
Although GWAS provide a list of markers that predispose to a certain disease or trait, they fail to 118 identify the tissues where the genetic causality arises. Given that we can test all filtered GWAS 119 signals for eQTL overlap, we can attempt to answer this question. In order to do so, we need to 120 know not only whether co-localizing GWAS and eQTL variants are tagging the same functional effect, 121 as inferred by RTC, but also the tissue-wide activity of the eQTL in question. We expect that weighing 122 the probability of GWAS and eQTL variants being due to the same functional effect with the tissue 123 sharing of the eQTL should increase our power in detecting the causal tissue behind the genetic 124 associations of a GWAS trait. To do so, for each eQTL in a given tissue that co-localizes with a GWAS 125 variant, we divide the probability of GWAS variant and eQTL tagging the same functional variant, 126 with the sum of tissue sharing probabilities of that eQTL in that tissue. This enables us to weigh the 127 GWAS-eQTL probabilities so that tissue specific eQTLs will contribute to a tissue's GWAS enrichment 128 more so than eQTLs that are shared with many other tissues. Next, for each disease in each tissue 129 we divide the sum of the normalized GWAS-eQTL probabilities from the previous step with the 130 number of independent eQTLs in the tissue, thereby controlling for the differential power of 131 discovery amongst the 44 tissues, and this is defined as our enrichment metric. We show that by 132 using our normalization technique we can significantly reduce (Mann-Whitney p = 1.5e-21, 133
Supplementary Figure 11 ) the correlation between the number of eQTLs in the tissues and the 134 GWAS enrichment metric, thus allowing us to estimate the relative contribution of tissues to the 135 genetic causality of a trait. 136
We investigated the overall pattern in tissue causality of GWAS traits and looked at specific 137 examples. Therefore, for each GWAS trait we rank our normalized enrichment metric for each of the 138 tissues. Those tissues that are ranked higher are estimated to contribute more to the genetic 139 causality of a GWAS trait. We discover that liver is the top tissue implicated in most of the GWAS 140 traits (12%), which include, expectedly, variety of lipid measurements 15, 16 and uric acid levels 17 141 (Figure 4a, Supplementary Figure 12 , Supplementary Table 5 ). Brain tissues are the top tissues 142 relating to traits like height 18 , schizophrenia 19, 20 , and age of onset of puberty 21 . Furthermore, for 143 traits where we have a biological prior of a causal tissue and where this tissue is assayed in GTEx, this 144 tissue tends to be the most likely tissue discovered by our methodology. For example, the top causal 145 tissue for coronary heart disease is coronary artery followed by liver; for schizophrenia the top 146 tissues are brain tissues and for lipid metabolism traits like total cholesterol levels the top tissue 147 tends to be liver (Figure 4b, c, d) . Thus, we show that by having access to eQTLs from multiple 148 tissues and controlling for the tissue specificity of eQTLs using our novel methodology, we can 149 estimate the relevant tissues from which the genetic causality of GWAS traits arise. 150
Since we estimated the tissue causality profiles for GWAS traits, we can compare the causal genes 151 for the GWAS associations between tissues likely contributing to the genetic causality of GWAS traits 152 and those that are not. We examined the rs12740374 variant in the 1p13 locus, which is not only 153 associated with coronary artery disease 22, 23 and lipid measurements 24 , but is also one of the few 154 GWAS non-coding loci where the mechanistic causes are well established 25 . Liver is a key tissue in 155 both heart disease and lipid measurements (Figure 4b, d) , and in liver the causal gene for the 156 rs12740374 association is correctly identified as SORT1 25 , P(Shared) = 1. In tissues that do not 157 contribute highly to the genetic causality of these traits, like testis and whole blood, we incorrectly 158 identified another nearby gene, PSRC1, as the putative causal gene, P(Shared) = 0.96 and 0.97, 159 respectively (Figure 5 , Supplementary Table 6 ). Importantly, the tissues where SORT1 is correctly 160 identified contribute significantly (Mann-Whitney p = 0.0007) more to the genetic causality of heart 161 disease and lipid levels than tissues where the causal gene is different (Supplementary Figure 13) . 162
This result shows the importance of identifying the causal tissues for GWAS traits, before stating 163 which genes may be responsible for these associations. 164
Finally, we asked how different diseases with shared pathophysiology differ with respect to which 165 tissues contribute to their genetic causality. To this end we investigated autoimmune and 166 cardiometabolic diseases and used hierarchical clustering to group the individual diseases according 167 to their relative tissue causality profiles. Among the autoimmune diseases we find that Crohn's 168 disease and ulcerative colitis form a cluster, whereas celiac disease has a different tissue causality 169 profile. Type 1 diabetes and lupus seem most similar to each other and rheumatoid arthritis, vitiligo, 170 and psoriasis appear markedly different when compared to other autoimmune disorders (Figure 6a) . 171
For cardiometabolic diseases, blood pressure related traits, coronary heart disease and type 2 172 diabetes form a cluster while stroke, where a strong effect in the brain is observed, is the outlier in 173 these types of disorders (Figure 6b ). We demonstrate that by comparing the tissue causality profiles 174 of GWAS diseases we can begin to disentangle the common as well as diverging biology underlying 175 their development. 176
Here we describe a novel approach that is designed to estimate the causal tissues underlying the 177 genetic causality of GWAS traits, using eQTLs identified by the GTEx consortium. Given the tissue 178 and sample size limitations, there is still room for improvement in determining true tissue causality 179 profiles for GWAS traits. However, our analysis represents an unbiased and complete profiling of the 180 tissue contributions to GWAS genetic causality in an unprecedented scale. As the sample sizes and 181 the number of tissues assessed for eQTLs, and our resolution of the genetic etiology of complex 182 disorders increase, we expect our methodology to yield even more powerful conclusions. We 183 believe this type of approach will be paramount in the interpretation of new GWAS results using a 184 publically available dataset, like GTEx, and will aid in the design of downstream functional 185 experiments to identify the mechanistic causes of complex disorders and traits, as well as new 186 avenues of treatment and prevention. 187
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